Podcasts about viatris

This week's episode dives into COPD treatment. When considering inhaler devices, what is the best strategy for COPD patients? Host Amy Attaway, MD, MS, associate director of the COPD Center at  Cleveland Clinic welcomes Anthony Anzueto, MD, professor of medicine at the University of Texas Health Science Center and chief of the pulmonary section for the South Texas Veterans Healthcare System in San Antonio.Support for this podcast is brought to you by Viatris and Theravance BioPharma.

This episode covers: Cardiology This Week: A concise summary of recent studies Hypertension in the elderly The digital twin in cardiology Snapshots Host: Emer Joyce Guests: Carlos Aguiar, Gianfranco Parati, Nico Bruining, Joost Lumens Want to watch that episode? Go to: https://esc365.escardio.org/event/1804 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Nico Bruining, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Joost Lumens has declared to have potential conflicts of interest to report: research grants from Medtronic (all grants paid to institute, Maastricht University). Gianfranco Parati has declared to have potential conflicts of interest to report: honoraria for lectures by Omron, Merck, Viatris, Somnomedics. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Join Isabel and Jade as they wrap up Season 9 of the podcast with special guest Dennise Broderick, President and Managing Director, Galen Pharma.  In this episode, Jade and Dennise discuss her move from academia to the pharmaceutical industry, her lifelong ambition to be a leader and how she approaches hard decisions in business.  A little more on EMJ GOLD's guest… Dennise is Managing Director and President at Galen – a pharmaceutical company based in Northern Ireland focused on pain management, dermatology and gastroenterology. There, she is responsible for all the aspects of the company's operations, marketing and governance across its various sites throughout the UK and Europe. Previously, Dennise has held positions at Pfizer, Hospira, Zeneus and Viatris – most recently working as the Country Manager at Ipsen. 

This episode covers: Cardiology This Week: A concise summary of recent studies Relevance and management of ventricular ectopic beats  Lp(a) in cardiovascular risk management Mythbusters: A vegetarian diet lowers cardiovascular risk Host: Susanna Price Guests: Carlos Aguiar, Thomas Deneke, Kausik Ray Want to watch that episode? Go to: https://esc365.escardio.org/event/1802 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Thomas Deneke, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Kausik Ray declared to have potential conflicts of interest to report: research grants from Amarin, Amgen, Daiichi Sankyo, Merck Sharp & Dohme, Pfizer, Regeneron, and Sanofi, consultant for Abbott, Amarin, Amgen, AstraZeneca, Bayer, Biologix, Boehringer Ingelheim, Cargene Therapeutics, CRISPR, CSL Behring, Eli Lilly and Company, Esperion, Kowa Pharmaceuticals, NewAmsterdam Pharma, Novartis, Novo Nordisk, Pfizer, Regeneron, Resverlogix, Sanofi, Scribe Therapeutics, Silence Therapeutics, Vaxxinity, and Viatris, honoraria for lectures from Novartis, BI, AZ, Novo Nordisk, Viatris, Amarin, Biologix Pharma, Sanofi, Amgen, Esperion, Daiichi Sankyo, Macleod and stock options New Amsterdam Pharma, Pemi 31, SCRIBE Therapeutics. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: New drug is looked at for T1D prevention, a new stem cell method is tested for beta cell transplanation without immunosuppresion drugs, the FDA okays the first fast-acting biosimilar insulin, Lilly lowers price of Zepbound, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX New research in type 1 diabetes prevention launches. Nektar Therapeutics and TrialNet will evaluate a drug currently used for exzema for patients with new onset stage 3 type 1 diabetes The drug is RezPeg – that's a shortened version of the name (rezpegaldesleukin)   This will be a study of about 70 adults and children and will launch this year. The new study will use a mixed meal tolerance test (MMTT) to measure the efficacy of rezpegaldesleukin or placebo for preserving C-peptide area under the curve over a 12-month duration comprised of a 6-month treatment period and a 6-month follow-up. Secondary objectives include pharmacokinetics, pharmacodynamics, and additional disease assessments including HbA1c levels and patient insulin requirements. Rezpegaldesleukin is being developed as a self-administered injection for a number of autoimmune and inflammatory diseases. https://www.prnewswire.com/news-releases/nektar-announces-clinical-trial-agreement-to-evaluate-rezpegaldesleukin-in-patients-with-new-onset-type-1-diabetes-mellitus-302383052.html XX NLS Pharmaceutics (NLSP) and Kadimastem announced successful completion of a pre-IND meeting with the FDA for iTOL-102, a potential diabetes treatment. iTOL-102 combines Kadimastem's IsletRx cells (stem cell-derived pancreatic islets) with iTolerance's immunomodulator iTOL-100, aiming to cure Type 1 Diabetes without requiring life-long immune suppression. The treatment was evaluated at the Diabetes Research Institute at the University of Miami School of Medicine, where it demonstrated functional insulin release and disease reversal in animal models. Based on FDA feedback, the companies are updating plans for safety toxicology studies and First-in-Human clinical trials. IsletRx is a clinical-grade product comprising human pancreatic islet-like cells capable of secreting insulin, offering a scalable source of insulin-producing cells to address donor islet shortages. The technology can detect glucose levels and produce required amounts of insulin and glucagon.   XX FDA has signed off on a rapid-acting insulin biosimilar for the first time. The agency has given a thumbs up to Sanofi's Merilog (insulin-aspart-szjj) as the first biosimilar to Novo Nordisk's NovoLog for patients with diabetes. Merilog will be provided by prefilled pen in a 3 mL dose or in a multiple-dose 10 mL vial. It is for adults and pediatric patients age 6 and older.     NovoLog and Novo Nordisk's other rapid-acting insulin follow-on Fiasp are among the drugs subject to government price negotiations under the Inflation Reduction Act. The new prices will be enacted at the start of next year. In July 2021, the FDA approved Biocon and Viatris' Semglee (insulin glargine-yfgn) as the first biosimilar to Lantus. Five months later, the U.S. regulator endorsed Eli Lilly's version of the drug, called Rezvoglar (insulin glargine-aglr). https://www.fiercepharma.com/pharma/fda-signs-sanofis-biosimilar-first-novo-nordisks-rapid-acting-novolog XX Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from cheap, compounded copies of weight loss medications. The company launched 7.5 mg and 10 mg vials of tirzepatide, sold under the brand name Zepbound, which typically cost $599 and $699, respectively. However, they are now available for $499 per month for patients paying without insurance. This applies to the first fill and all refills that are delivered every 45 days. Additionally, the company lowered the prices of the 2.5 mg and 5 mg vials to $349 and $499 per month, respectively. The company, which has seen a significant boost in profits from Zepbound and Mounjaro – essentially the same drug with different FDA-approved uses – announced that the new vials and pricing are exclusively available through the company's self-pay pharmacy, LillyDirect Self Pay Pharmacy Solutions. https://www.bloomberg.com/news/articles/2025-02-25/zepbound-cost-for-vials-cut-to-battle-cheaper-copycats XX Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a five-year period and could reach $102 billion next year, an analysis by Health and Human Services' inspector general found. The findings also come as the Trump administration weighs the fate of a Biden administration proposal that would require Medicare and Medicaid to cover GLP-1s for weight loss. The biggest spikes in usage were for Rybelsus, Novo Nordisk's once-daily GLP-1 tablet, and for the company's weekly injectable Ozempic, whose spending about doubled every year under review. https://www.axios.com/2025/02/25/medicare-spending-surge-diabetes-drugs XX Tandem Diabetes Care has secured a new FDA clearance for its insulin dose-calculating algorithm, opening up Control IQ for use in adults with Type 2 diabetes. The expanded label was based on data from a pivotal, randomized trial of more than 300 people with Type 2 diabetes, comparing its use to manual multiple daily injections. Tandem said it plans to present the study's results at the annual Advanced Technologies & Treatments for Diabetes meeting scheduled for next month in Amsterdam. https://www.fiercebiotech.com/medtech/tandem-diabetes-care-insulin-dosing-algorithm-nets-fda-clearance-type-2-diabetes XX Drugs approved for diabetes and obesity might be useful for the treatment of cognitive and mental health disorders, according to a new paper published in Nature Mental Health.   The study reviewed and integrated data from both preclinical and clinical studies to gather evidence on the possible effects of these drugs GLP1s and semaglutide  in conditions such as dementia, substance use disorders, psychotic disorders, mood and anxiety disorders, and eating disorders.     The study found promising but still preliminary evidence that GLP-1RAs could be beneficial over a range of cognitive and mental health disorders. These drugs have shown potential in improving cognition, reducing addictive behavior, and alleviating depression and anxiety. More data from robustly designed studies (i.e., randomized controlled trials) are needed to better understand GLP-1RAs' prospective efficacy and safety profile, especially with long-term use. https://medicalxpress.com/news/2025-02-diabetes-drugs-mental-health-treatment.html XX The FDA  issued draft guidance that includes recommendations to support the development and marketing of safe and effective AI-enabled The guidance, if finalized, would be the first guidance to provide comprehensive recommendations for AI-enabled devices throughout the total product lifecycle, providing developers with an accessible set of considerations that tie together design, development, maintenance, and documentation recommendations to help ensure the safety and effectiveness of AI-enabled devices. FDA is requesting public comment on this draft guidance by April 7. The agency also released draft guidance for the use of AI to support regulatory decision-making for drug and biological products. https://www.mddionline.com/artificial-intelligence/fda-issues-draft-guidance-for-ai-enabled-devices-seeks-public-feedback XX Congrats to Mila Clarke who some of you may know better as Hangry Woman on social. She has developed a great app called Glucose Guide and the Nutrition Assistant portion of that app went live this week. Glucose Guide is a web and mobile app that offers diabetes meal tracking, coaching, resources, recipes and community to those looking for help managing diabetes. MEAL AND BLOOD SUGAR TRACKING FEATURES.

This podcast was supported by Viatris. The views and opinions expressed in this podcast are those of the individual speakers and do not necessarily reflect those of Viatris or EMJ. Speakers have received honoraria for their participation. Explore the challenges and solutions for managing opioid-induced constipation (OIC) in this insightful podcast, featuring discussions from a leading gastroenterologist and an expert pain specialist. Topics covered include: Defining OIC prevalence, underlying mechanisms, and impact on patient wellbeing The risks and limitations of laxative use in managing OIC The role of peripherally acting mu-opioid receptor antagonists Strategies for improved communication and monitoring

Disease-modifying therapies work, and, as a result, people with MS are living longer. With half the MS population over the age of 55, it's never been more urgent to understand how the process of aging impacts MS and how MS impacts the process of aging. In this special episode of RealTalk MS, Dr. Leorah Freeman discusses the many factors associated with aging with MS. This special episode of RealTalk MS is sponsored by Viatris. SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/V202 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode V202 Guests: Dr. Leorah Freeman Privacy Policy

Transforming Your Mental Health Journey with MS- Episode 179 - Transcript Join host Dr. Stephanie Buxhoeveden with guest neuropsychologist Meghan Beier, who joins us to dive deeper into how various therapeutic approaches can transform your mental health journey with MS. Whether you're living with MS or a care partner, you'll find helpful explanations of different therapies and actionable insights that can empower you on your journey. If you're here looking for support, education, or inspiration, this episode is here to help you build resilience, live well, and thrive with MS. Thank you to Viatris for their support of this podcast episode. Disclaimer: This podcast provides general educational information. Can Do MS does not endorse, promote, or recommend any product, service, or diet associated with the content of this program.

Increased restrictions for HRT menopause treatment, as Pharmac finds ways shore up supply of oestradiol patches. It's changing its main funded brand to Estradiol TDP Mylan from supplier Viatris from next July. In order to ensure supply, it'll be the only funded brand available by December 2025. Menodoctor Clinical Director, Linda Dear, says those who can't use the Mylan brand will have other options. "Most women who get on with other, non-Mylan brands will get on with gel fine - but it means they'll have to start probably thinking about that transition." LISTEN ABOVESee omnystudio.com/listener for privacy information.

Flu Vaccines: Advancements, Challenges, and Global Impact – Expert Insights on Vaccine Platforms and Immune ResponsesIn this phenomenal episode, three leading experts in the field of vaccinology and immunology dive into the science behind various vaccine platforms and immune responses. Tune in as they explore the evolution of vaccines, from early, early vaccine platforms to cutting-edge technologies, and discuss the advantages and disadvantages of each approach.  In a dynamic, educational conversation, we hear about the quest for the holy grail, the crucial role of CD8 T-cells, and the global challenges of vaccine accessibility and hesitancy.Join Professor Ab Osterhaus, ESWI Executive Committee Member and Director of the Center of Infection Medicine and Zoonosis Research at the University of Veterinary Medicine Hannover, Germany; ESWI Board Member Florian Krammer, Professor of Vaccinology at the Department of Microbiology at the Icahn School of Medicine at Mount Sinai in New York, and Professor for Infection Biology at the Medical University of Vienna; and ESWI Associate Member Carolien van de Sandt, Senior Research Fellow, Department of Microbiology and Immunology at the Peter Doherty Institute, Australia in this thought-provoking discussion on the future of vaccines and global health.With the support of Moderna and Viatris.

In this episode, Nick sits down with Andrew Enrietti, Chief People Officer, Viatris, to explore his unique journey from finance to HR and the pivotal role of leadership in building a supportive, people-first workplace culture. Andrew sheds light on mental health as a universal issue and analyses the meaning of work-life balance. He also shares his belief in the power of transparency, trust and strong team relationships. Tune in for insights on the value of calculated career shifts, how participating in sports can cultivate leadership skills, and why setting both short- and long-term goals are essential for success. Andrew also dives into the future of HR, exploring how AI can personalize employee L&D, enhancing both engagement and productivity. Join us as we delve into the practices that create a resilient, people-centered workplace.

MS affects almost 3 times as many women as men, often affecting women of childbearing age. In this special episode of RealTalk MS, Dr. Riley Bove answers some of the important questions about the impact of MS on a woman's pregnancy and the impact of pregnancy on a woman's MS. This special episode of RealTalk MS is sponsored by Viatris. SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/V201 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode V201 Guests: Dr. Riley Bove Privacy Policy

Shield Therapeutics CEO Anders Lundstrom and CFO Santosh Shanbhag joined Steve Darling from Proactice to share its released an unaudited Q3 2024 trading update revealing $7.2 million in net revenues from ACCRUFeR prescriptions, with an average net selling price of $167 per prescription. Excluding July's summer buying trends, the NSP averaged $192 in Q3, and Shield anticipates maintaining this level into Q4. Shield looks to gain traction, especially in the United States, where it partners with Viatris, deploying a sales force of 100 to promote ACCRUFeR. To support its objective of achieving cash flow positivity by 2025, Shield has expanded its working capital financing with Sallyport Commercial Finance from $10 million to $15 million. Additionally, Shanbhag also noted that steps are being taken to improve Shield's cash position, including a planned 10% cost reduction and expanded financing from Sallyport, which he believes will support Shield's objective of reaching cash flow positivity by the end of 2025. #proactiveinvestors #shieldtherapeuticsplc #lse #stx #pharma #ACCRUFeR #IronDeficiency #PharmaUpdate #FinancialGrowth #Biotech #ProactiveInvestors #CashFlowPositive #USMarket #HealthcareInnovation#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

October 28, 2024Season 6 | Episode 39Unlock the secrets of an ancient tradition's surprising link to stock market success. Discover how the Halloween strategy could transform your investing game, along with an intriguing peek into the origins of Halloween itself. We'll dive into the heart of the market's pulse, from the S&P 500's "Magnificent 7" to undervalued gems waiting to be discovered as earnings season heats up. Join Brad and the team as we navigate the twists and turns of global events and their ripple effects on financial markets, from oil price shifts driven by geopolitical tensions to the political stage's influence on indices.Explore the unpredictable dance of the bond market and how it might impact your wallet, especially if you're dealing with variable rate debt. We'll uncover the stories of companies like Ford, defying expectations, and examine the significance of bond market volatility and its historical echoes. As the political landscape looms large, we caution against making hasty investment choices based on election predictions and instead spotlight undervalued opportunities like Viatris. Whether you're a seasoned investor or just curious about the financial world, this episode promises a well-rounded snapshot of the economic landscape and potential pathways to profit.** For informational and educational purposes only, not intended as investment advice. Views and opinions are subject to change without notice. For full disclosures, ADVs, and CRS Forms, please visit https://heroldlantern.com/disclosure **To learn about becoming a Herold & Lantern Investments valued client, please visit https://heroldlantern.com/wealth-advisory-contact-formFollow and Like Us on Youtube, Facebook, Twitter, and LinkedIn | @HeroldLantern

Luis Herrero entrevista a Joao Madeira, presidente de la Fundación Viatris para la Salud.

Want to support Global Value? https://www.interactivebrokers.com/mkt/?src=gvy1&url=%2Fen%2Fwhyib%2Foverview.php https://www.patreon.com/GlobalValue David Einhorn owns 42 stocks in his portfolio worth 2.2 billion dollars. In this video we're covering his top 10 biggest positions. Starting with #10 Viatris. David Einhorn is the founder and president of Greenlight Capital, a "long-short value-oriented hedge fund" he started in 1996. Over the next decade, the fund returned 26% annually, easily beating the market. He receives extensive coverage in the financial press for his fund's performance, his investing strategy and his positions. Einhorn was included in Time magazine's Time 100 list of "100 most influential people in the world" in 2013. According to Investopedia, his net worth was around US$1.5 billion in June 2019. Thank you for watching. ❤️ Please support the channel by checking out our affiliates. All commissions are reinvested to improve the quality of videos! - TIKR is the website I use for financial data in my videos. Join me and 250,000+ investors worldwide by using TIKR in your investment analysis. Referral link - https://www.tikr.com/globalvalue - Check out Seeking Alpha Premium and score an exclusive 20% off plus a free 7 day trial! Affiliate link - https://www.sahg6dtr.com/H4BHRJ/R74QP/ - Try Sharesight https://www.sharesight.com/globalvalue (remember you get 4 months free if you sign up for an annual subscription!) #davideinhorn #davideinhornportfolio #davideinhornstocks #greenlightcapital #greenlightportfolio #stocks2024 #stockmarket2024 #macro #superinvestors #investing2024 #investing #stockportfolio #portfolio #portfoliodeepdive #greenlightstocks

Want to support Global Value? https://www.interactivebrokers.com/mkt/?src=gvp1&url=%2Fen%2Fwhyib%2Foverview.php https://www.patreon.com/GlobalValue David Einhorn owns 42 stocks in his portfolio worth 2.2 billion dollars. In this video we're covering his top 10 biggest positions. Starting with #10 Viatris. David Einhorn is the founder and president of Greenlight Capital, a "long-short value-oriented hedge fund" he started in 1996. Over the next decade, the fund returned 26% annually, easily beating the market. He receives extensive coverage in the financial press for his fund's performance, his investing strategy and his positions. Einhorn was included in Time magazine's Time 100 list of "100 most influential people in the world" in 2013. According to Investopedia, his net worth was around US$1.5 billion in June 2019. Thank you for watching. ❤️ Please support the channel by checking out our affiliates. All commissions are reinvested to improve the quality of videos! - TIKR is the website I use for financial data in my videos. Join me and 250,000+ investors worldwide by using TIKR in your investment analysis. Referral link - https://www.tikr.com/globalvalue - Check out Seeking Alpha Premium and score an exclusive 20% off plus a free 7 day trial! Affiliate link - https://www.sahg6dtr.com/H4BHRJ/R74QP/ - Try Sharesight https://www.sharesight.com/globalvalue (remember you get 4 months free if you sign up for an annual subscription!) #davideinhorn #davideinhornportfolio #davideinhornstocks #greenlight #greenlightportfolio #stocks2024 #stockmarket2024 #hedgefund #stocks #superinvestors #investing2024 #investing #stockportfolio #portfolio #portfoliodeepdive #investmentstrategies

Mick Barry TD chats to Gareth O'Callaghan following the announcement that Viatris is too close it's Little Island plant Hosted on Acast. See acast.com/privacy for more information.

The stats for the percentage of men with erectile dysfunction are pretty staggering:Approximately 41.5% of men in the UK reported experiencing ED, according to a 2018 study conducted by Viatris, Queen's University Belfast, and Pfizer. And it only increases with age: - Around 29.3% for men aged 18-39 - About 45.6% of men aged 40 and overAccording to research by the British Association of Urological Surgeons, 50-55% of British men between 40 and 70 years old have some degree of ED. Ken Schafer can count himself as one of those men who also struggled with ED, and, like many men, he went straight for Viagra to cure his problem. After some time, that failed to work, so he started to look for other solutions. His journey led him to write a book, ‘A Practical Guide to Managing Erectile Dysfunction' and to help now men like himself struggling with ED. In particular, he signposts his clients to specific practitioners who can support them in becoming more fit and healthy and, as a result, remove the requirement for pharmaceuticals and other medical interventions.I found Ken's honesty and willingness to be vulnerable about this particular challenge with ED very refreshing. And if you have a title for his job, please share it with me!Web: https://www.healthysexualitywithken.com/Social media:https://www.instagram.com/healthys3xualitywithken/https://www.tiktok.com/@healthys3xualitywithkenhttps://www.youtube.com/@HealthySexualityWithKenLLChttps://www.facebook.com/healthys3xualitywithkenllchttps://twitter.com/HSWKen Get full access to Sex Advice for Seniors at www.sexadviceforseniors.com/subscribe

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly.   This episode covers: Cardiology This Week: A concise summary of recent studies State-of-affairs in hypertension treatment Anticoagulation in pregnancy Statistics Made Easy : Accuracy and AUC    Host: Perry Elliott Guests: Carlos Aguiar, Gianfranco Parati, Julie De Backer Want to watch that episode? Go to: https://esc365.escardio.org/event/1152   Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Julie De Backer and Nicolle Kraenkel have declared to have no potential conflicts of interest to report.  Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Novo Nordisk, Sanofi. Terumo, Medtronic. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics. Gianfranco Parati has declared to have potential conflicts of interest to report: honoraria for lectures by Omron, Viatris, Merck, Recor, Somnomedics. Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.

He's been arrested. He's CIS gender with a wife and kids. Rabbi Mike Moskowitz is also an orthodox Jew'is and he is one of the biggest supporters of the queer community. Rabbi Moskowitz is the Scholar-in-Residence for Trans and Queer Jewish Studies at Congregation Beit Simchat Torah, the world's largest LGBT synagogue. He is a deeply traditional and radically progressive advocate for trans rights and a vocal ally for LGBTQ inclusivity. Rabbi Moskowitz received three Ultra-Orthodox ordinations while learning in the Mir in Jerusalem and BMG in Lakewood, NJ. He is a Wexner Field Fellow, Senior Rabbinic Fellow at the Hartman Institute, and the author of Textual Activism, Graceful Masculinity, and Seasonal Resistance. His newest book, Covenantal Allyship, will be available this year. Rabbi Moskowitz's writings can be found at www.rabbimikemoskowitz.comWe met in person at Temple shir Shalom in West Bloomfield. Rabbi Moskowitz was speaking at the synagogue and wishing to always be an ally for the Queer community, I went.The CF community, every community has a queer population and that's why I felt it was important to talk about this.To reach Rabbi Mike Moskowitz www.cbst.orgTo learn more about him and to order his books https://www.rabbimikemoskowitz.com Please like, subscribe, and comment on our shows, wherever you get your podcasts.Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Thanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en

About Dr. Bollinger Dr. Bollinger is a board-certified optometrist and a Fellow of the American Academy ofOptometry which demonstrates her commitment to excellence and lifelong learning inher profession. She has participated in advisory board meetings & also as a KeyOpinion Leader for companies such as Alcon, Ocular Therapeutix, Novartis, ScienceBased Health, Viatris, and TearScience. She enjoys educating which allows herto share her passion and expertise on dry eye and ocular surgery with other eye careprofessionals and the public. She earned her undergraduate degree in Biology at MiamiUniversity in Ohio and her Doctor of Optometry degree at Ohio State University. Sheserved as an adjunct clinical professor at Ohio State University from 2006-2012. Shehas participated as a clinical investigator in several FDA pharmaceutical and surgicalstudies for dry eye disease, presbyopia, topical steroids, intraocular lenses, andDemodex blepharitis. Her primary career goal is to help patients achieve optimal visionand eye health through personalized and evidence-based care.As an optometrist with 30+ years of experience, she strives to provide exceptional eyecare to patients with various ocular conditions and needs. She has extensiveexperience in perioperative surgical eye care, managing thousands of cases ofrefractive, cataract, and cornea surgeries throughout her career. Dr. Bollinger is alsoskilled in medical eye care, treating patients with glaucoma, diabetes, maculardegeneration, and dry eyes. Helping patients with ocular surface disease, including dryeye, meibomian gland disease, & blepharitis is her primary passion. She currently sees patients at Jacksoneye in Lake Villa, Illinois.

In this episode, our experts discuss the recommended clinical anti-TNF treatments for inflammatory bowel disease in Europe and the USA and the patient factors that should be considered in patient decision-making. This podcast series has been supported by Viatris, who were not involved in the creation of this content.

This introductory episode provides an introduction to the role anti-TNF therapies play in the management of inflammatory bowel disease, ulcerative colitis and Crohn's disease This podcast series has been supported by Viatris, who were not involved in the creation of this content.

Our gastroenterology experts consider the patient's underlying comorbidities when making treatment decisions regarding anti-TNFs. They also evaluate the safety profile and risks, particularly for elderly patients This podcast series has been supported by Viatris, who were not involved in the creation of this content.

In this episode, our experts discuss the use of combination therapy involving anti-TNFs and immunomodulators, with a focus on the synergy and immunogenic effects, clinical trial outcomes, and the conversations that need to be had with patients. This podcast series has been supported by Viatris, who were not involved in the creation of this content.

Expanding the discussion of the use of anti-TNF biosimilars, in this episode, our expert panel provides insights on switching and the handling of adalimumab biosimilars. This podcast series has been supported by Viatris, who were not involved in the creation of this content.

In this penultimate episode of the series on anti-TNFs for inflammatory bowel disease, our expert gastroenterologists discuss treatment options for difficult-to-treat Crohn's disease and ulcerative colitis, including recent views and decision-making. This podcast series has been supported by Viatris, who were not involved in the creation of this content.

In this final episode of the series, the discussion focuses on the role of therapeutic drug monitoring and current practices, as well as how treatment decisions are made for patients refractory to anti-TNFs. The guests conclude by discussing the future of anti-TNFs and identifying the remaining gaps in the care of patients with inflammatory bowel disease. This podcast series has been supported by Viatris, who were not involved in the creation of this content.

Our expert gastroenterologists continue their discussion of the side effects and risks of anti-TNFs, including infection, vaccine immunogenicity, and tuberculosis (TB) risk, as well as monitoring approaches. This podcast series has been supported by Viatris, who were not involved in the creation of this content.

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über einen Terrorabschlag bei Tesla, die Teppich-Enttäuschung bei Bayer und aussichtsreiche M&A-Kandidaten. Außerdem geht es um Fresenius Medical Care, Novo Nordisk, Nio, Apple, Target, Walmart, Lufthansa, Fresenius Medical Care, LEG Immobilien, ThyssenKrupp, Fonds DJE - Mittelstand & Innovation (WKN: A14SK0), Berenberg Aktien Mittelstand (WKN: A2JF7M), DWS Concept Platow (WKN: DWSK62), Exxon Mobil, Bristol Myers Squibb, AT&T, Zealand Pharma, Viking Therapeutics, Tenet Healthcare, Sarepta Therapeutics, Tripadvisor, Wingstop, Victoria's Secret, Global Holdings, Viatris, Multi Axxion Europa Fonds (WKN: 765377), Invesco EQQQ Nasdaq-100 (WKN: 801498) und WisdomTree NASDAQ 100 3x Daily Leveraged (WKN: A3GL7E). Wir freuen uns an Feedback über aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.UnitedHealth is facing an antitrust probe by the DOJ regarding potential anticompetitive effects. Despite challenges like high labor costs, UHS, a hospital operator, saw revenue growth in 2023. Veradigm is set to delist after missing a Nasdaq deadline. Nurse leaders report burnout and turnover in their roles. A ransomware attack at an urgent care provider may have exposed personal information of over 516,000 people. Healthcare Dive provides insights for healthcare leaders, including articles on AI implementation, social determinants of health, and healthcare data breaches, covering a wide range of topics such as hospitals, payers, health IT, government policies, finances, medical groups, and telehealth. Healthcare Dive is operated by Industry Dive, providing journalism and insights for decision-makers in competitive industries.Viatris pays $350 million to acquire two drugs from Idorsia for heart attacks and lupus in phase 3 testing. Ginkgo acquires gene editing tools through the buyout of Proof Diagnostics, founded by Feng Zhang. Incannex reports that psilocybin therapy reduced anxiety in a small study. Women's health company Obseva plans to wind down operations and lay off staff. Viking's obesity drug showed promising results in a phase 2 trial, potentially rivaling drugs from Eli Lilly and Novo Nordisk. The rise of obesity drug treatments is reshaping the pharma industry with significant advancements and changes, as companies make strategic moves to enhance their portfolios and address unmet medical needs.Gatorade has unveiled Gatorade Water, their first unflavored water product, with a digital-heavy marketing campaign focused on wellness. Estee Lauder's marketing mix modeling use was discussed at the eTail Palm Springs conference, showcasing their balance between brand and performance marketing. Dick's Sporting Goods has enlisted Kathryn Hahn and Will Arnett for an ad campaign highlighting e-commerce convenience. Food and beverage brands are putting a modern spin on retro packaging to appeal to consumers' emotions. Mod Op has acquired RTO+P for more creative firepower in a competitive market. Marketing Dive explores mobile messaging's influence on consumer behavior in 2024, as well as upcoming events and industry news.The recent awarding of Johnson & Johnson's Dr. Paul Janssen Award for Biomedical Research to MIT professor and Moderna co-founder Robert Langer is discussed in the text, recognizing his impactful innovations in drug delivery. Langer's work in nanoparticle drug delivery has led to advancements in biopharma, particularly in the technology behind mRNA vaccines. The text also highlights Langer's role as a scientific advisor to a new CRO aiming to improve clinical trials through technology. Additionally, it addresses the staffing challenges faced by CROs since the pandemic and explores strategies for retaining talent in the research industry, emphasizing the importance of adapting to new technologies and approaches to enhance efficiency in clinical trials and improve patient care.

Das Baselbieter Biotechunternehmen Idorsia bekommt Geld aus den USA. Die Firma Viatris bezahlt 350 Millionen Dollar an Idorsia für die Entwicklung von zwei Medikamenten. Für Idorsia sei das ein wichtiger Schritt, sagen Fachleute. Weitere Themen: * Kantonslabor Baselstadt beanstandet Hygiene in Restaurants * Basler Privatspitäler behandeln mehr Patientinnen und Patienten

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Laurin Meyer und Holger Zschäpitz über Erleichterung bei Delivery Hero, stählerne Probleme bei Thyssenkrupp und Nvidias Fahrt auf der Überholspur. Außerdem geht es um Amazon, Alphabet, Microsoft, Cisco, Twilio, Uber, Lyft, Upstart, ProSiebenSat.1, Coca-Cola, Mondelez, McCormick, Hershey, PepsiCo, Kraft Heinz, Novo Nordisk, Nu Holdings, AT&T, Apple, Microsoft, First Advantage Corp., Canadian Pacific, General Electric, Solarwinds, HCA Healthcare, CVS Health, Oracle, Warner Bros. Discovery, Block, Mettler-Toledo, JD, Alibaba, Stellantis, Apple, Five Below, Home Depot, Nike, Salesforce, GoDaddy, Booking, Paramount Global, HP, Dr. Horton, Stoneco, Chevron, Occidental, Sirius XM, Viatris, Kenvue, Johnson&Johnson, Bayer, Goldman Sachs, Invesco Aerospace & Defense Portfolio (WKN: A2JNSR) und SPDR S&P Aerospace & Defense ETF (WKN: A1JYC4) und iShares MSCI Europe Quality Factor (WKN: A12DPM). Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hier findet ihr alle AAA-Bonus-Episoden bei WELT – dazu den AAA-Newsletter und noch weitere WELTplus-Inhalte: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Professors Wytske Fokkens and Joaquim Mullol discuss the burden of smell loss and the emerging science on how inflammation drives olfactory dysfunction in patients with CRSwNP. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Professor Wytske Fokkens, MD, PhD has received consultation/speaker fees from Novartis, Sanofi, GSK and Dianosic.  Professor Joaquim Mullol, MD, PhD reports have received research grants, participated in clinical trials, been a member of Speaking Bureaus and Advisory Boards from Allakos, AstraZeneca, Glenmark, GSK, Menarini, MSD, Mitsubishi-Tanabe, Noucour/Uriach Group, Novartis, Optinose, Proctor & Gamble, Sanofi-Genzyme, Regeneron Pharmaceuticals, Viatris. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2400013 v1.0 01/2024 MAT-US-24000221 v1.0 - P Expiration Date: 01/08/2026

Adrenaline is key in terms of acute management, don't delay and don't be apprehensive about it Encourage patients to attend specialist follow up to refine practical management for safety and quality of life GPs to provide information precisely in referral, which may help to prioritise who is seen, especially if the allergy is unknown   Host: Dr David Lim | Total Time: 42 mins Guest: Dr Celia Zubrinich, Allergy Specialist   The views, information or opinions expressed in Healthed podcast episodes are those of the individuals involved and do not necessarily represent those of Viatris. Viatris does its utmost to ensure completeness, relevance and currency of information, but is not responsible for verifying the accuracy of all information shared by guests.   Register for our fortnightly FREE WEBCASTSEvery second Tuesday | 7:00pm-9:00pm AEDT Click here to register for the next oneSee omnystudio.com/listener for privacy information.

Today we are discussing iron deficiency in Aboriginal and Torres Strait Islander peoples, with Dr Sam Heard, the medical director of the Central Australian Aboriginal Congress. This podcast is sponsored by Viatris. With MJA news and online editor, Sam Hunt. 15 minutes. 

Today we are discussing iron deficiency in the general Australian population, with Professor Arumugam Manoharan, a specialist physician in clinical haematology at St George Private Hospital in Sydney. This podcast is sponsored by Viatris.  With MJA news and online editor, Sam Hunt. 23 mins.

In this third episode, Solomon Tesfaye and Oliver Binns-Hall consider the transformative potential for diabetic neuropathy care. They identify the importance of integrated patient care and the need for early-stage screening and diagnosis, discussing the evolving role of the podiatrist, and the need for a well co-ordinated foot care service. They also consider innovative screening solutions and the improvements needed in the chronic management of this condition. This content has been supported by Viatris

In this final episode, Solomon Tesfaye and Oliver Binns-Hall explore the dynamic landscape of the recognition and treatment of diabetic neuropathy across diverse clinical realities in various countries. They discuss the challenges, and solutions that can help improve the management of diabetic neuropathy in different healthcare settings worldwide.  This content has been supported by Viatris

In this second podcast, Kevin Boehnke and Dan Clauw consider the experiences of the healthcare professional when it comes to treating fibromyalgia. They emphasise the significance of shared decision-making between both the patient and practitioner. They also explore the available treatment options, and consider the role of non-pharmacological approaches in managing this condition. Speakers Dr Kevin Boehnke Research Assistant Professor, Department of Anaesthesiology and the Chronic Pain and Fatigue Research Centre, University of Michigan Medical School, Ann Arbor, USA Dr Boehnke received his doctorate from the University of Michigan School of Public Health in Environmental Health Sciences in 2017. Dr Boehnke's current research focuses on therapeutic applications of cannabis and psychedelics where his goal is to rigorously assess appropriate use of these substances and to help address the public health harms caused by their criminalisation. He is also a yoga instructor and he himself lives with fibromyalgia. Professor Daniel Clauw Professor of Anasthesiology, Internal Medicine of Rheumatology and Psychiatry, and the Chronic Pain and Fatigue Research Centre, University of Michigan Medical School, Ann Arbor, USA Professor Clauw serves as Director of the Chronic Pain and Fatigue Research Centre at the University of Michigan, USA and co-directs the Research Development Core and Pre-Doctoral Programs. His research is committed to clinical care and research into the central nervous system. He is an international expert in chronic pain disorders, such as fibromyalgia, where he incorporates a multitude of methods ranging from patient-reported outcomes to functional and chemical neuroimaging, and phenotyping, and as such, has been critical in helping elucidate the importance of the central nervous system in chronic pain conditions. This content has been supported by Viatris

In the second episode, Solomon Tesfaye and Ollie Binns-Hall unravel the intricate relationship between diabetes and pain. They focus on the current approaches to identifying diabetic peripheral neuropathy and explore the risk factors, and current detection and management approaches, identifying the challenges associated with managing this multifaceted condition.   This content has been supported by Viatris

In the first episode, Solomon Tesfaye and Ollie Binns-Hall explore the pressing issue of the diabetes epidemic and its most prevalent microvascular complication: neuropathy. They discuss the identification and characterisation of these critical aspects of diabetes and explore the causes, symptoms, and challenges of diagnosing neuropathy within the broader context of diabetes.   This content has been supported by Viatris

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Laurin Meyer und Holger Zschäpitz über neue Hoffnung aus China, eine verheerende IPO-Statistik und eine ungewöhnliche Boomerang-Aktion bei Salesforce. Außerdem geht es um PDD, JD.com, Li Auto, Baidu, Activision Blizzard, Microsoft, Goldman Sachs, Klaviyo, Instacard, Maplebear, Ford, General Motors, Stellantis, AutoNation, Lithia Motors, UPS, Amazon, Starbucks, Tesla, Toyota, SentinelOne, Gitlab, Confluent, Snowflake, Cloudflare, Wolfspeed, MongoDB, Unity Software, HubSpot, Spotify, Trade Desk, Plug Power, Uber, Rivian, Lucid, Draftkings, Doordash, Teladoc, Mettler-Toledo, Apellis Pharma, Colgate-Palmolive, Clorox, New Fortress Energy, NextEra Energy, Macy's, GM, Toll Brothers, Kraft Heinz, Bunge, Tyson Foods, Walgreens, Pfizer, Viatris, HP, Western Digital, Intel, Micron Technologies, Juniper, United Steel, Paramount, Verizon, Liberty Media, iShares Edge MSCI World Value Factor (WKN: A12ATG), Global BIT Internet Leaders (WKN: A2JR0J)​​, ARK Innovation (WKN: A14Y8H), 10X DNA (WKN: DNA10X) und Han-Gins Tech Megatrend ETF (WKN: A2JR0J). Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Figure It Out: Adaptations and Staying Active - Episode 150 - Transcript - In this episode, we're excited to feature our guest and past program participant, Danica King, who is thriving with MS thanks to her amazing ability to “figure it out.” We're excited to have Danica on this episode while we celebrate Can Do Month, which is in honor of our founder Jimmie Heuga. Jimmie wore many hats including that of an athlete, Olympian, husband, father, and pioneer in the MS Community. Jimmie was all about discovering what you “Can Do” to be able to enjoy the things you love and even try new adventures while living with MS. There are a lot of parallels between Jimmie's Can Do Spirit and Danica's own story. Danica is passionate about adaptive sports and has participated in many sports and activities. Through her story she encourages us to “figure it out” whether that's seeking out adaptive equipment or asking for help. You can check out more of Danica's story in her book Figure It Out: Snapshots Of My Journey With Multiple Sclerosis and follow her on Instagram @FigureItOutMS Thank you to Biogen and Viatris for their support of Can Do Month and this podcast episode. In this episode we mention a variety of resources, a few are below for your reference. MSAA Cooling Distribution Program MSAA Equipment Distribution Program Sportable NMSS Navigator

In this first podcast, Kevin Boehnke and Dan Clauw delve into the patient's perspective regarding the burden of fibromyalgia. They explore the impact of fibromyalgia on a person's life, with Kevin sharing his personal experiences. Both experts also evaluate the significance of non-pharmaceutical treatment options for managing this condition. Speakers Dr Kevin Boehnke Research Assistant Professor, Department of Anaesthesiology and the Chronic Pain and Fatigue Research Centre, University of Michigan Medical School, Ann Arbor, USA Dr Boehnke received his doctorate from the University of Michigan School of Public Health in Environmental Health Sciences in 2017. Dr Boehnke's current research focuses on therapeutic applications of cannabis and psychedelics where his goal is to rigorously assess appropriate use of these substances and to help address the public health harms caused by their criminalisation. He is also a yoga instructor and he himself lives with fibromyalgia. Professor Daniel Clauw Professor of Anasthesiology, Internal Medicine of Rheumatology and Psychiatry, and the Chronic Pain and Fatigue Research Centre, University of Michigan Medical School, Ann Arbor, USA Professor Clauw serves as Director of the Chronic Pain and Fatigue Research Centre at the University of Michigan, USA and co-directs the Research Development Core and Pre-Doctoral Programs. His research is committed to clinical care and research into the central nervous system. He is an international expert in chronic pain disorders, such as fibromyalgia, where he incorporates a multitude of methods ranging from patient-reported outcomes to functional and chemical neuroimaging, and phenotyping, and as such, has been critical in helping elucidate the importance of the central nervous system in chronic pain conditions. This content has been supported by Viatris

Empresas como Viatris luchan para seguir mejorando la calidad de vida de millones de pacientes en el mundo. El CEO de la empresa en España, Joao Madeira, nos lo cuenta en 'JELO'

In this episode, we hear about biosimilar insulin: its safety, efficacy, what sets it apart from biologic insulin, and when it should be considered for use. Host Aaron Lohr talks with Irl Hirsch, MD, professor of medicine at the University of Washington Medicine Diabetes Institute. This episode is made possible through an unrestricted, educational grant from Viatris. Show notes are available at https://www.endocrine.org/podcast/enp69-biosimilar-insulin — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

In this episode, we hear about biosimilar insulin: its safety, efficacy, what sets it apart from biologic insulin, and when it should be considered for use. Host Aaron Lohr talks with Irl Hirsch, MD, professor of medicine at the University of Washington Medicine Diabetes Institute. This episode is made possible through an unrestricted, educational grant from Viatris. Show notes are available at https://www.endocrine.org/podcast/enp69-biosimilar-insulin — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

In this episode, we hear about biosimilar insulin: its safety, efficacy, what sets it apart from biologic insulin, and when it should be considered for use. Host Aaron Lohr talks with Irl Hirsch, MD, professor of medicine at the University of Washington Medicine Diabetes Institute. This episode is made possible through an unrestricted, educational grant from Viatris. For helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast